Abstract
Breast cancer is the most common crucial cancer in women worldwide. The tumor marker Carcinoma Antigen 15-3 is frequently used for screening and monitoring breast cancer. Carcinoma antigen 15–3 (CA15-3) is used to monitor the prognosis for patients after treatment. This study aims to estimate the level of serum tumor marker CA15-3 in different age groups. Participants women diagnosed with breast cancer living in Iraq were admitted to the Middle East lab (private lab), Al-Harthia city. The study involves 176 females aged from 30 to 80 years. Data was collected from the period between March to November 2021. An automated electrochemistry luminescence immunoassay system (ROCHE E170, Germany) measured serum CA15-3 levels. When the CA15-3 marker level was above or below the cut-off value of 25 U/mL, the marker was counted positive or negative. The current study reveals that CA15-3 in the age group between (33-39) was the highest in 39 years (27.7 U/ml). Furthermore, 47 years exhibited the highest level of CA15-3 (150 U/ml) among (40-49 years) category. Meanwhile, 55 years participants showed the highest level of CA15-3 (101 U/ml) in (50-59 years) age group. 66 years old, on the other hand, showed an elevated level of CA15-3 (72 U/ml) compared to other participants in the (60-69) age group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
